Avaleht › Melanoom › Florida › Orlando
Melanoom kliinilised uuringud linnas Orlando, FL
15 uuringut haiguse Melanoom jaoks otsivad osalejaid linnas Orlando ja selle ümbruses (umbes 30 miili raadiuses). Avage uuring, et näha, kes saab osaleda ja kuidas võtta ühendust uuringumeeskonnaga.
Ametlik uuringutekst (inglise keeles)
Otsite osalejaid uuringusse? Esitlege seda selle lehe tipus – $99 30 päeva eest →
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
VärbamineFaas 2
- AdventHealth Medical Group Oncology Research at Celebration, Kissimmee · 16 mi kaugusel
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
VärbamineFaas 3
- Orlando Health Cancer Institute, Orlando
A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
VärbamineFaas 2
- Nemours Children's Hospital, Orlando
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
VärbamineFaas 3
- Orlando Health Cancer Institute, Orlando
- Health Central, Ocoee · 10 mi kaugusel
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
VärbamineFaas 1
- AdventHealth, Orlando
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
VärbamineFaas 2
- Orlando Health Cancer Institute, Orlando
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
VärbamineFaas 1
- Sarah Cannon Research Institute - Florida Cancer Specialists, Orlando
Project: Every Child for Younger Patients With Cancer
VärbamineVaatlusuuring
- AdventHealth Orlando, Orlando
- Arnold Palmer Hospital for Children, Orlando
- Nemours Children's Hospital, Orlando
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
VärbamineFaas 1/2
- AdventHealth Celebration, Celebration · 17 mi kaugusel
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
VärbamineFaas 1/2
- Clermont Oncology Center, Clermont · 24 mi kaugusel
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
VärbamineFaas 1
- Florida Cancer Specialists - Lake Nona, Orlando
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
VärbamineFaas 1/2
- Orlando Health Cancer Institute (Melanoma/NSCLC), Orlando
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
VärbamineFaas 1/2
- Orlando Health Cancer Institute, Orlando
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
VärbamineFaas 3
- Orlando Health Cancer Institute, Orlando
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
VärbamineFaas 1/2
- Research Site 137, Orlando
- Research Site 118, Celebration · 17 mi kaugusel
Melanoom uuringud teistes linnades
- Houston, TX59 uuringut
- New York City, NY38 uuringut
- Los Angeles, CA34 uuringut
- Nashville, TN33 uuringut
- Pittsburgh, PA31 uuringut
- Boston, MA26 uuringut
- Philadelphia, PA23 uuringut
- San Francisco, CA22 uuringut
- Durham, NC21 uuringut
- Atlanta, GA21 uuringut
- St. Louis, MO21 uuringut
- Salt Lake City, UT21 uuringut
Muud uuringud linnas Orlando
- Mitteväikerakuline kopsuvähk44 uuringut
- Rasvumine31 uuringut
- Metastaatiline vähk29 uuringut
- Ülekaalulisus27 uuringut
- Alzheimeri tõbi25 uuringut
- 2. tüüpi diabeet24 uuringut
- Vähk (kõik liigid)24 uuringut
- Rinnavähk23 uuringut
- Munasarjavähk22 uuringut
- Haavandiline koliit22 uuringut
- Kopsuvähk21 uuringut
- Käär- ja pärasoolevähk19 uuringut
Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.